Crossject SA

Paris Stock Exchange ALCJ.PA

Crossject SA Capital Expenditure for the year ending December 31, 2023: USD -7.07 M

Crossject SA Capital Expenditure is USD -7.07 M for the year ending December 31, 2023, a 2.55% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Crossject SA Capital Expenditure for the year ending December 31, 2022 was USD -7.25 M, a 5.38% change year over year.
Crossject SA Capital Expenditure for the year ending December 31, 2021 was USD -7.66 M, a -2.92% change year over year.
Crossject SA Capital Expenditure for the year ending December 31, 2020 was USD -7.45 M, a -50.78% change year over year.
Crossject SA Capital Expenditure for the year ending December 31, 2019 was USD -4.94 M, a -31.85% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

Paris Stock Exchange: ALCJ.PA

Crossject SA

CEO	Mr. Patrick Alexandre
IPO Date	Feb. 20, 2014
Location	France
Headquarters	6 Rue Pauline Kergomard
Employees	105
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Drugstores & Retail Pharmacies

Description

Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is used for of treatment migraines and cluster headaches; Adrenaline for treating anaphylactic shock; Hydrocortisone that is used for treatment of acute adrenal crisis; Midazolam for treating epileptic seizure; Naloxone used for treatment of overdose; Apomorphine, for treating temporary paralysis in parkinson's disease; Methotrexate used for treatment of rheumatoid arthritis; and Terbutaline, for treating severe asthma crisis. The company was founded in 1997 and is based in Dijon, France.

Key trends

Past 5 years